Manufacturer record
Caremax Formulations: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
4 batches manufactured by Caremax Formulations (Himachal Pradesh) were declared Not of Standard Quality between October 2019 and October 2021. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: CLT-14750, Diclofenac Sodium Tablets IP (DECIFEN-50 TABLETS (exp Feb 2023). RDTL Chandigarh (CDSCO lab) found it not of standard quality: Disintegration Test. Listed in the October 2021 alert.
Records by type
4 records linked to Caremax Formulations in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Diclofenac Sodium Tablets IP (DECIFEN-50 TABLETS | Batch CLT-14750Mfg Mar 2020 · Exp Feb 2023 | Disintegration TestDisintegration | RDTL ChandigarhCDSCO lab | Oct 2021 |
| Paracetamol Tablets IP (CAREMOL TABLETS) | Batch CLT-14398Mfg Dec 2019 · Exp Nov 2022 | DissolutionDissolution | RDTL ChandigarhCDSCO lab | Sep 2021 |
| TELMISARTAN TABLETS IP 40 MG | Batch CLT-14747Mfg Mar 2020 · Exp Feb 2022 | Uniformity of weight & DissolutionDissolution | RDTL ChandigarhCDSCO lab | Apr 2021 |
| Amikacin Sulphate Injection IP (AMIKACARE 500) | Batch CLI-6868Mfg Nov 2018 · Exp Oct 2020 | Particulate MatterParticulate matter | RDTL ChandigarhCDSCO lab | Oct 2019 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.